Menu
Recruiting NCT07062198

Combined Metabolic Activator Supplementation in Subjects Diagnosed With Alzheimer's Disease

Phase III Interventional Alzheimer Disease

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Combined metabolic activators, Collagen and maltodextrin.
Who it may be relevant to
Registry conditions: Alzheimer Disease. Basic parameters: from 50 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Turkey (Türkiye)
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

A Phase 3, Randomised, Double-blinded, Placebo-controlled Study to Evaluate the Efficacy, Tolerability, and Safety of Combined Metabolic Activator Supplementation in Subjects Diagnosed With Alzheimer's Disease

Overview

This randomised, double-blinded, placebo-controlled study aims to establish metabolic improvements in subjects diagnosed with Alzheimer's Disease (AD) by treatment with CMA2 including N-acetyl-L-cysteine (NAC), L-carnitine-L-tartrate (LCAT), nicotinamide (niacinamide), and L-serine. Participants will take the drug CMA2 or a placebo twice a day for 26 weeks. They will visit the clinic 4 times for checkups and tests.

Detailed description

This will be a randomised, double-blinded, placebo-controlled, multi-centre Phase 3 study with the aim to establish metabolic improvements in subjects diagnosed with AD by dietary supplementation with CMA2, including NAC, LCAT, niacinamide, and L-serine. The study will be performed at approximately 9 clinical sites in Turkey and aims to include a total of 676 evaluable subjects (up to 845 randomised).

The study comprises four clinical visits. Consenting subjects will be screened for eligibility (Visit 1; screening) according to study-specific eligibility criteria within 28 days prior to randomisation and start of IMP administration. Eligible subjects will be randomised on Day 1 (Visit 2) to 26 weeks of b.i.d. oral administration of either CMA2 or placebo (1:1). The first dose will be administered at the study clinic. The subjects will be observed for 2 hours post dose for the development of any allergic reactions or intolerance after taking the first dose. Subjects who cannot tolerate the study agents will be withdrawn from the study.

Visits at the study site will be performed at Week 13 (Visit 5) and Week 26 (Visit 8; end of treatment). Monthly telephone contacts will be scheduled with the patients. At the telephone visits IMP compliance, Concomitant medication and adverse event will be addressed.

The following clinical scales will be used to assess the effect of CMA2 on cognition and daily life activity: MMSE, ADAS-Cog, and ADCS-ADL. Blood samples will be collected for advanced plasma metabolomics, proteomics, and lipidomics analysis. Whole genome sequencing will not be performed.

Optional blood samples will be collected for p- tau217, Nfl, GFAP, and S-Urate analysis. Optional Saliva and faeces sampling for oral and gut microbiome will be collected. CSF samples will be optional collected for determination of Abeta42, total-Tau, p-Tau181 levels and Neurofilament light chain concentrations, and for advanced CSF metabolomics, proteomics, and lipidomics analysis. These samples will be decided by each investigator and will be analysed as exploratory endpoint.

Interventions

  • Drug Combined metabolic activators
    A total of 20g of CMA2 with strawberry aroma and colouring agent will be given. The IMP will be provided as a soluble powder packed as individual dosages in identical sachets. The powder should be dissolved in 200 ml preferably cold water before use. The powder can also be used on yoghurt or other food. The subjects will take two daily oral doses of the IMP, one dose just after breakfast and one dose just after dinner. Subjects who cannot tolerate (e.g., diarrhoea) taking full dose will be withd
  • Other Collagen and maltodextrin
    As placebo, a total of 20g of compound primarily containing collagen and maltodextrin will be administered. Placebo contains strawberry aroma flavouring and colouring agent.

Primary outcome measures

  • Change in Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-Cog) score from baseline to end-of-treatment [Time frame: Visit 1, Visit 5 (13 weeks), Visit 8 (26 weeks)]
Secondary outcome measures (12)
  • Change in Mini Mental State Examination (MMSE) score from baseline to end-of-treatment [Time frame: Visit 1, Visit 5 (13 weeks), Visit 8 (26 weeks)]
  • Change in Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL) score from baseline to end-of-treatment [Time frame: Visit 1, Visit 5 (13 weeks), Visit 8 (26 weeks)]
  • To evaluate compliance daily two doses treatment in patients [Time frame: Visit 5 (13 weeks), Visit 8 (26 weeks)]
  • Change in body weight from baseline through-out the study [Time frame: Visit 1, Visit 5 (13 weeks), Visit 8 (26 weeks)]
  • Change in body height from baseline through-out the study [Time frame: Visit 1, Visit 5 (13 weeks), Visit 8 (26 weeks)]
  • Change in BMI from baseline through-out the study [Time frame: Visit 1, Visit 5 (13 weeks), Visit 8 (26 weeks)]
  • Change in waist and hip circumference from baseline [Time frame: Visit 1, Visit 5 (13 weeks), Visit 8 (26 weeks)]
  • Change in blood pressure from baseline [Time frame: Visit 1, Visit 5 (13 weeks), Visit 8 (26 weeks)]
  • Change in heart rate from baseline [Time frame: Visit 1, Visit 5 (13 weeks), Visit 8 (26 weeks)]
  • Change in red blood cell count from baseline [Time frame: Visit 1, Visit 5 (13 weeks), Visit 8 (26 weeks)]
  • Change in platelet count from baseline [Time frame: Visit 1, Visit 5 (13 weeks), Visit 8 (26 weeks)]
  • Change in hemoglobin concentration from baseline [Time frame: Visit 1, Visit 5 (13 weeks), Visit 8 (26 weeks)]

Eligibility criteria

Inclusion criteria

  • Men and women of non-childbearing potential ≥ 50 years of age.
  • Diagnosed with AD and at the Screening visit having the scores of ADAS-Cog ≥ 12 and GDS≥ 4.
  • Stable AD treatments and clinical course for at least 1 month.
  • Females of childbearing potential must have documented tubal ligation or hysterectomy; or be post-menopausal (defined as 12 months of amenorrhoea \[in questionable cases a blood sample with simultaneous follicle stimulating hormone (FSH) 25-140 IE/L and oestradiol <200 pmol/Lis confirmatory\]).
  • Able to give written informed consent for participation in the study by the patient and/or legal representatives.

Exclusion criteria

  • History of stroke.
  • History of brain trauma < 14 days.
  • Uncontrolled diagnosed depression.
  • Uncontrolled (HbA1C > 8) type 1 or type 2 diabetes.
  • Severe swallowing problems.
  • PEG-feeding.
  • Chronic diarrhoea.
  • Chronic kidney disease with S-Creatinin > 1,30 mg/dl.
  • Active bronchial asthma at the time of screening.
  • History of phenylketonuria (contraindicated for NAC).
  • Known allergy for substances used in the study.
  • Known malignancies.
  • Use of dietary supplements such as vitamins, omega-3 products, or plant stanol/sterol products later than one (1) week prior to inclusion.
  • Use of anti-microbial agents later than one (1) week prior to inclusion.
  • Drug and/or alcohol abuse.
  • Subjects considered as inappropriate for this study for any reason (noncompliance etc.) per investigator assessment.
  • Administration of another new chemical entity (defined as a compound that has not been approved for marketing) or has participated in any other clinical study that included drug treatment with the last administration within 3 months prior to administration of IMP in this study.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Double blind
Primary purpose
Supportive care

Study locations

Turkey (Türkiye) · 8 centers
  • Department of Neurology and Neuroscience, Faculty of Medicine, Alaaddin Keykubat Universit — Alanya
  • Ataturk University, Faculty of Medicine, Department of Neurology, Erzurum, Turkey; Movemen — Erzurum
  • Behavioural Neurology and Movement Disorders Unit, Department of Neurology, Istanbul Facul — Istanbul
  • Haydarpaşa Numune Training and Research Hospital, University of Health Sciences Istanbul — Istanbul
  • Sancaktepe Şehit Prof. Dr. İlhan Varank Training and Research Hospital, University of Heal — Istanbul
  • SB Haseki Training and Research Hospital, Istanbul, University of Health Sciences Istanbul — Istanbul
  • Sultan Abdülhamid Han Training and Research Hospital, University of Health Sciences Istan — Istanbul
  • Umraniye Training and Research Hospital, University of Health Sciences Istanbul — Istanbul

Identifiers

NCT: NCT07062198 · SB-AD-002

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗